- Fund & Investor Interest
- Solebury Trout Updates
- Market Commentary
- IPO News
- Expert Interactions
- Conference Snippet
- Industry Snippets
- Solebury Trout Talks

IPO News: Filed S-1/A: Turning Point Therapeutics Launches ~7.4mm Share IPO with $16.00 - $18.00 Marketing Range
Turning Point Therapeutics
NASDAQ: TPTX
Initial Filing Date: 03/21/19
Launch Date: 04/08/19
Price Range: $16.00 - $18.00
Shares Offered (Pre-Shoe | mm): 7.4
Primary Shares (mm): 7.4
Secondary Shares (mm): 0.0
Amount Offered (@ Midpoint)(mm): $125.0
% Secondary: 0.0%
Shares Outstanding (mm): 27.8
Market Value at Midpoint (mm): $471.9
Offering as % of Market Value: 26.5%
Bookrunners: GS | LEER | WFS
Co-Managers: CANA
Major Holders: Cormorant Asset Management | LAV Prime | OrbiMed Private Investments | SR One | Foresite Capital Fund | venBio Partners | Robert Adelman | Yishan Li (Co-Founder) | Jingrong Jean Cui (Co-Founder)
Industry: Healthcare
Description: Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing novel small molecule, targeted oncology therapies to address key limitations of existing therapies and improve the lives of patients.
Note: Emerging Growth Company
Launch Link: S-1/A